To date, the US FDA has approved PI3K-targeting drugs such as idelalisib, copanlisib, and duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) 47. The gene discussed is PIK3CD; the disease is B-cell chronic lymphocytic leukemia.